ResMed Director Christopher G. Roberts Unloads 25,000 Shares (RMD)
ResMed (NYSE:RMD) Director Christopher G. Roberts unloaded 25,000 shares of ResMed stock on the open market in a transaction that occurred on Thursday, May 29th. The stock was sold at an average price of $49.73, for a total transaction of $1,243,250.00. Following the transaction, the director now directly owns 101,988 shares in the company, valued at approximately $5,071,863. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on RMD shares. Analysts at Northland Securities downgraded shares of ResMed from a “market perform” rating to an “underperform” rating in a research note on Tuesday. They now have a $40.00 price target on the stock. Separately, analysts at Deutsche Bank upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research note on Thursday, April 24th. They now have a $52.00 price target on the stock. Finally, analysts at Morgan Stanley reiterated an “equal weight” rating on shares of ResMed in a research note on Thursday, April 24th. They now have a $46.08 price target on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $45.90.
ResMed (NYSE:RMD) traded down 0.30% on Friday, hitting $50.06. The stock had a trading volume of 425,601 shares. ResMed has a 52 week low of $41.52 and a 52 week high of $57.34. The stock has a 50-day moving average of $49.05 and a 200-day moving average of $46.8. The company has a market cap of $7.025 billion and a price-to-earnings ratio of 22.03.
ResMed (NYSE:RMD) last released its earnings data on Wednesday, April 23rd. The company reported $0.63 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter in the prior year, the company posted $0.58 earnings per share. The company’s quarterly revenue was up 3.7% on a year-over-year basis. Analysts expect that ResMed will post $2.49 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, June 17th. Investors of record on Tuesday, May 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 2.00%. The ex-dividend date of this dividend is Friday, May 16th.
ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.